Safety concerns about perisurgical epoetin treatment: should we add antiplatelet drugs to perisurgical epoetin alfa treatment?
Basora
Misericordia
M
Fita
Guillermina
G
Matute
Purificación
P
Díaz-Ricart
Maribel
M
D000740:Anemia / Q000517:prevention & control*; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D019918:Heart Valve Prosthesis Implantation; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D008946:Mitral Valve Stenosis / Q000601:surgery*; D011183:Postoperative Complications / Q000517:prevention & control; D011300:Preoperative Care / Q000379:methods*; D011994:Recombinant Proteins; D012307:Risk Factors; D016896:Treatment Outcome
D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa